Lyrica
Product Images NDC 21695-661

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 21695-661). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 01)

A drug facts panel showing a formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a factor for female patients. The formula is presented as a mathematical expression with variables including age (years), weight (kg), serum creatinine (mg/dL), and a multiplier of 0.85 for females.*

FDA Label Image

Chemical Structure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 02)

Chemical structure diagram of the active ingredient in Lyrica. The image shows a molecular formula with labeled functional groups including a carboxylic acid (CO2H) and an amine (NH2).*

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at doses of 25 mg, 100 mg, and 200 mg taken three times a day to a placebo. The graph illustrates patient improvement trends across these treatment groups.*

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Two lines compare Pregabalin 100 mg three times a day and placebo, illustrating patient response differences over various pain improvement levels.*

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Lyrica (pregabalin) at doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared to a placebo. The graph shows separate curves for each pregabalin dose and the placebo over the range of 0 to 100 percent improvement.*

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 06)

A line chart depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing effectiveness trends in pain improvement over a range of percentages.*

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 07)

A line graph depicting percent improvement in pain from baseline versus percent of patients improved. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing their respective trends in patient improvement percentages across various pain improvement levels.*

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 08)

This image is a bar chart showing responder rates (%) for different doses including placebo and 50 mg, 300 mg, and 600 mg daily in studies E1 and E3. The chart compares response rates across these dose groups, with annotations indicating statistical significance versus placebo and sample sizes at the bottom.*

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 09)

A line graph showing seizure reduction as median percent change from baseline versus dose (mg/day). It compares data from four studies (E1BD, E2TID, E3BD, and E3TID) with seizure reduction increasing with higher doses up to 600 mg/day. The graph displays statistical significance (p-values) for differences in seizure reduction at various doses versus placebo.*

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 10)

A line graph comparing the percent improvement in pain from baseline against the percent of patients improved for Lyrica (pregabalin) at daily doses of 300 mg, 450 mg, and 600 mg, plus a placebo group. The graph shows four distinct lines representing different dose responses over a range from 0 to 100 percent improvement.*

FDA Label Image

Figure (8fb45a78 B2d8 45dd B844 0de21d1fdde9 11)

A line graph comparing the estimated percentage of subjects without LTR over time (days) between two groups: Pregabalin and Placebo. The x-axis represents days from 0 to 180, and the y-axis represents the estimated percentage of subjects without LTR ranging from 0% to 100%. The Pregabalin curve shows a higher percentage of subjects without LTR over time compared to Placebo.*

FDA Label Image

Logo (8fb45a78 B2d8 45dd B844 0de21d1fdde9 12)

FDA Label Image

Logo (8fb45a78 B2d8 45dd B844 0de21d1fdde9 13)

FDA Label Image

Lyrica 25mg (8fb45a78 B2d8 45dd B844 0de21d1fdde9 14)

Lyrica 25 mg capsules packaging label showing 15 count. Each capsule contains 25 mg pregabalin. The label includes the NDC 21695-276-15, product ID PL027615, and indicates the product is manufactured by Pfizer Pharmaceuticals LLC, Vega Baja, PR. Packaged by Physician Partner, Thousand Oaks, CA, with storage instructions between 15°-30°C (59°-86°F).*

FDA Label Image

Lyrica 75mg (8fb45a78 B2d8 45dd B844 0de21d1fdde9 15)

Label for Lyrica 75mg capsules, bottle of 120, showing that each capsule contains 75mg Pregabalin. The label indicates the capsules are white/orange hard gelatin with black printing. It includes lot, expiration, and pricing details, identifies Pfizer Pharmaceuticals LLC as manufacturer, and Physician Partner as packager. Storage and safety warnings appear at the bottom.*

FDA Label Image

Lyrica 100mg (8fb45a78 B2d8 45dd B844 0de21d1fdde9 16)

Lyrica 100mg capsules label from Rebel Distributors Corp showing a package of 60 capsules. The label indicates each capsule contains 100mg of pregabalin. It is produced by Pfizer Pharmaceuticals LLC, labeled by Physician Partner, Thousand Oaks, CA, with storage instructions at controlled room temperature 15-30°C.*

FDA Label Image

Lyrica 100mg (8fb45a78 B2d8 45dd B844 0de21d1fdde9 17)

Lyrica 150 mg capsules packaging label by Rebel Distributors Corp. The label states one capsule contains 150 mg of the active ingredient. It features a Physician Partners logo, an NDC number (21695-682-30), lot and expiration dates, and storage instructions for controlled room temperature (15°-30°C). The label is printed on a white background with blue and red accents.*

FDA Label Image

Lyrica 200mg (8fb45a78 B2d8 45dd B844 0de21d1fdde9 18)

Lyrica 200mg capsules packaging label from Physician Partner, containing 90 capsules. The label indicates each capsule contains 200mg of the active ingredient. The product ID is RL066390, manufactured by Pfizer Pharmaceuticals LLC. Storage information and handling instructions are also present on the label.*

FDA Label Image

Lyrica 300mg (8fb45a78 B2d8 45dd B844 0de21d1fdde9 19)

Lyrica 300mg capsules packaging label with 90 capsules per bottle. The label includes the NDC 21695-664-90 and states each capsule contains 300mg of the active ingredient. Distributed by Physician Partner and manufactured by Pfizer Pharmaceuticals LLC, with storage instructions and safety warnings visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.